Update on the management of Philadelphia chromosome positive chronic myelogenous leukemia: role of nilotinib
Josephine Emole,1 Taiwo Talabi,2 Javier Pinilla-Ibarz1 1Department of Malignant Hematology, 2Moffitt Program for Outreach Wellness Education and Resources, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA Abstract: Chronic myelogenous leukemia (CML) is a pluripotent stem cell dise...
Guardado en:
Autores principales: | Emole J, Talabi T, Pinilla-Ibarz J |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://doaj.org/article/781e9f4f539e475b828a4cf785a7d206 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
The effect of imatinib and nilotinib on blood calcium and blood potassium levels in chronic myeloid leukemia patient: a literature review
por: Muhammad Darwin Prenggono, et al.
Publicado: (2021) -
A combination of sorafenib and nilotinib reduces the growth of castrate-resistant prostate cancer
por: Archibald M, et al.
Publicado: (2016) -
Survival impact of adherence to tyrosine kinase inhibitor in chronic myeloid leukemia
por: Yundeok Kim, et al.
Publicado: (2021) -
Novel Treatment Strategies Utilizing Immune Reactions against Chronic Myelogenous Leukemia Stem Cells
por: Maiko Matsushita
Publicado: (2021) -
Isolation of Mycobacterium branderi, an unusual species from an acute myelogenous leukemia patient
por: Majid Marjani, et al.
Publicado: (2014)